Clinical Trial Update: DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating DS3201 in combination with ipilimumab for metastatic prostate, urothelial, and renal cell cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• DS3201
• ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING